Lexology January 16, 2026
Speaking at the 2026 J.P. Morgan Healthcare Conference, Hogan Lovells global regulatory partners Elizabeth Jungman and Brian Carey moderated a panel discussion with U.S. Food and Drug Administration (FDA) Deputy Chief of Staff Samuel Doran and FDA Office of the Commissioner Senior Advisor Karim Mikhail. They discussed the agency’s priorities for 2026, workforce changes, national security concerns, and FDA’s goal of accelerating medical product approvals. The panelists described expanding collaboration with HHS, global regulators, and venture investors, especially on issues like biosimilar reform, drug pricing, and government procurement. They touched down on FDA’s publication of complete response letters, rare disease regulatory paradigm shifts, and the Commissioner’s National Priority Voucher (CNPV) and FDA PreCheck.
Kicking off the J.P. Morgan panel conversation...
Today's Sponsors
Today's Sponsor